Wojewódzki Zespół Lecznictwa Psychiatrycznego W Olsztynie
Olsztyn, Polen
Behandlung & Zugang
- Angebotene Behandlungenesketamine (Spravato)
- ZugangswegDurch ein nationales Programm übernommen
- Kosten & Übernahme (Registerstatus)Covered by NFZ (drug programme B.147)
- ErstattungNFZ drug programme B.147 - leczenie chorych na depresję lekooporną So funktioniert die Erstattung in Europa →
- Telefon+48 89 678 53 53
- Websitehttps://wzlp.pl
Über diesen Anbieter
The Provincial Psychiatric Care Complex (WZLP) in Olsztyn runs the B.147 esketamine (Spravato) program through its Mental Health Center and publishes one of the clearest enrollment pathways in Poland: qualification is led by a named psychiatrist, with phone sign-up Monday-Wednesday 13:00-14:00 at a dedicated number, and a required certificate from the treating physician confirming all program criteria plus copies of prior psychiatric records. The hospital also operates general psychiatric wards, a clinical psychogeriatric ward, day wards and specialist outpatient clinics at al. Wojska Polskiego 35.
Leistungen & Programme
- General psychiatric wards
- Clinical psychogeriatric ward
- Day psychiatric ward with psychiatric rehabilitation subunit
- Child and adolescent psychiatric ward and day rehabilitation ward for children
- Specialist outpatient clinics and community treatment team
- Mental Health Center (Centrum Zdrowia Psychicznego)
- Spravato (esketamine) drug program for treatment-resistant depression, NFZ program B.147
Häufige Fragen
How exactly do I sign up for the Spravato program in Olsztyn?
Call +48 89 678 52 74 Monday-Wednesday between 13:00 and 14:00. For the first consultation bring a certificate from your treating physician confirming all program criteria and a copy of your psychiatric treatment records; final qualification is made by the center's psychiatrist.
What must the certificate from my doctor confirm?
Per the hospital's published criteria: ICD-10 diagnosis F33.1 or F33.2; treatment resistance (no response to at least two adequate antidepressant trials in the current moderate-to-severe episode, and no more than five antidepressants tried in this episode); at least a second depressive episode; current episode lasting at least six months; exclusion of borderline personality disorder and bipolar disorder; no history of addiction; and contraindication, resistance or non-consent to ECT.
Is Spravato used alone?
No. Per the hospital's information and the drug's SmPC, within the program esketamine is used together with a second SSRI/SNRI antidepressant; otherwise reimbursement is not possible.
Verifizierung
- Lizenz / RegisterNFZ B.147
- Quellehttps://api.nfz.gov.pl/app-itl-api/queues?case=1&benefit=LECZENIE%20CHORYCH%20NA%20DEPRESJ%C4%98%20LEKOOPORN%C4%84
- Zuletzt verifiziert